Randall Beyl, MD
Rheumatology · Baton Rouge, LANPI 1356630958
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,525 of the $112,416 with a category attached, or 68.1%. 33 manufacturers reported payments, led by AbbVie at 57.1% of the total. Reporting peaked in 2022 at $24,227 and has fallen 67.0% since, to $7,996 in 2025. Among rheumatology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,004 payments — averaging $111.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64K
- Lilly USA, LLC$25K
- Novartis$8K
- Johnson & Johnson$6K
- GSK$3K
- AstraZeneca$2K
- plus $5K from 27 others
What the payments were for
- Consulting fees$8,9808%
- Speaking & faculty fees$76,52568%
- Travel & lodging$8,0897%
- Food & beverage$18,74917%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 334 | $64,179 |
| Lilly USA, LLC | 52 | $24,722 |
| Novartis | 76 | $7,880 |
| Johnson & Johnson(2 entities) | 94 | $6,236 |
| GSK | 88 | $2,636 |
| AstraZeneca(2 entities) | 62 | $1,568 |
| Pfizer | 70 | $1,025 |
| E.r. Squibb & Sons, L.L.C. | 61 | $1,008 |
| Amgen | 51 | $863 |
| UCB, Inc. | 18 | $360 |
| Janssen Scientific Affairs, LLC | 2 | $249 |
| Mallinckrodt Hospital Products Inc. | 10 | $229 |
| Radius Health, Inc. | 10 | $202 |
| Regeneron Healthcare Solutions, Inc. | 18 | $197 |
| Genentech USA, Inc. | 9 | $157 |
| ANI Pharmaceuticals, Inc. | 5 | $128 |
| Bristol Myers Squibb | 7 | $115 |
| Aurinia Pharma U.S., Inc. | 5 | $94 |
| Fresenius Kabi USA, LLC | 6 | $87 |
| Organon | 5 | $64 |
| Boehringer Ingelheim | 3 | $60 |
| Sanofi | 2 | $54 |
| Scilex Pharmaceuticals Inc. | 3 | $52 |
| Pacira Pharmaceuticals Incorporated | 2 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Bioventus LLC | 2 | $44 |
| Celltrion USA Inc. | 1 | $22 |
| Sobi, Inc | 1 | $18 |
| Alvogen Inc | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Antares Pharma, Inc. | 1 | $11 |
| Avion Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,416 in reported general payments places this provider in the 90th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 308 | $2,306,401 |
| Enbrel SureclickEtanercept | 178 | $1,326,885 |
| RinvoqUpadacitinib | 149 | $939,730 |
| Orencia ClickjectAbatacept | 151 | $860,221 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 35 | $781,710 |
| Xeljanz XrTofacitinib Citrate | 75 | $426,950 |
| BenlystaBelimumab | 87 | $424,391 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $402,017 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 39 | $340,176 |
| Taltz AutoinjectorIxekizumab | 42 | $335,709 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 26 | $311,040 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $278,400 |
| Cosentyx Unoready PenSecukinumab | 31 | $259,130 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $246,782 |
| TremfyaGuselkumab | 16 | $220,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga | $1,025 | $1,183,72751 claims |
| AbbVieRinvoq | $64,179 | $939,730149 claims |
| GSKBenlysta | $2,636 | $424,39187 claims |
| Johnson & JohnsonTremfya, Simponi | $6,236 | $361,86738 claims |
| AmgenOtezla, Enbrel, Prolia | $863 | $226,08148 claims |
| Radius Health, Inc.Tymlos | $202 | $150,03655 claims |
| UCB, Inc.Cimzia (2 Pack) | $360 | $137,29124 claims |
| Alvogen IncTeriparatide | $18 | $62,04416 claims |
| SanofiKevzara | $54 | $60,86114 claims |
| Lilly USA, LLCOlumiant | $24,722 | $27,67311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Baton Rouge
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Chad HilleBaton Rouge$52K
- Ronald CerutiBaton Rouge$29K
- Joseph NesheiwatBaton Rouge$18K
- Jen ErbilBaton Rouge$17K
- Hector MenaBaton Rouge$15K
- Stephen PolletBaton Rouge$14K
- Khanh HoBaton Rouge$12K
- Angele BourgBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.